Unveiling a Glycation Hot Spot in a Recombinant Humanized Monoclonal Antibody
Biotechnological companies and regulatory agencies are pursuing the complete characterization of protein therapeutics in every detail as a means to mitigate risks of product quality related safety issues. During the characterization of a recombinant humanized monoclonal antibody (referred to as rhuM...
Gespeichert in:
Veröffentlicht in: | Analytical chemistry (Washington) 2008-04, Vol.80 (7), p.2379-2390 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!